- Liz Highleyman | 31 October 2013
Almost all HIV-positive people with undetectable
viral load who switched to once-daily raltegravir (Isentress) maintained viral suppression, French researchers
reported at the 14th European AIDS Conference this month in
Brussels. In an effort ...
- Liz Highleyman | 31 October 2013
Higher baseline viral load, longer time to viral
suppression and low-level viraemia below the level of detection of standard
tests raise the risk of viral rebound amongst people with HIV on antiretroviral
therapy ...
- Liz Highleyman | 30 October 2013
The recently approved HIV integrase inhibitor dolutegravir (Tivicay) provides at least equivalent
antiviral efficacy and better tolerability compared with approved
antiretroviral drugs for treatment-naive people, according to data reported at
the 14th European
AIDS ...
- Liz Highleyman | 29 October 2013
Eighteen per cent of HIV-positive men
acquired hepatitis C virus (HCV) a second time after clearing the virus, with
some having third and fourth infections as well, according to findings from the
European ...
- Gus Cairns | 24 October 2013
Over
Europe as a whole, the proportion of people testing late for HIV decreased
between 2002 and 2010, a presentation at the 14th European AIDS Conference in
Brussels last week showed, and the ...
- Keith Alcorn | 22 October 2013
A switch to a cheaper injectable illicit drug led to a major
outbreak of HIV infection in Tel Aviv, Israel, and should serve as a warning signal for
other cities with apparently ...
- Liz Highleyman | 22 October 2013
HIV
treatment in the coming years will include novel antiretroviral agents and new
formulations such as long-acting injectables, as well as new strategies aimed
at improving adherence and minimising side-effects, it was reported ...
- Liz Highleyman | 22 October 2013
The HCV protease inhibitor faldaprevir added to pegylated interferon and
ribavirin increased the likelihood that HIV/HCV co-infected people would
achieve a sustained virological response at four weeks after completing treatment,
according to a ...
- Gus Cairns | 21 October 2013
A study presented at the 14th European AIDS Conference
last week found that the suicide rate in people with HIV in British Columbia,
Canada, had fallen 35-fold since 1996 and was now ...
- Liz Highleyman | 21 October 2013
Adding the direct-acting
hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported at the 14th European AIDS ...
- Liz Highleyman | 20 October 2013
A dual combination of lopinavir/ritonavir (Kaletra or Aluvia) plus
3TC (lamivudine, Epivir) as
first-line therapy produced good virological suppression regardless of baseline
viral load and was well tolerated in the multinational GARDEL study, ...
- Liz Highleyman | 20 October 2013
The experimental HIV integrase inhibitor GSK1265744 demonstrated rapid and potent antiviral
activity and good tolerability for treatment-naive people in the LATTE study,
according to a report at the 14th European
AIDS Conference this ...
- Keith Alcorn | 19 October 2013
Only 20% of people with HIV in Europe have fully suppressed
viral load, compared to an estimated 24% in sub-Saharan Africa, despite much
higher rates of HIV diagnosis in the European region, ...
- Gus Cairns | 18 October 2013
A new edition of the European
AIDS Clinical Society (EACS) guidelines for the treatment of HIV,
HIV and hepatitis C co-infection, and HIV with other co-morbidities were published in advance of
the 14th ...
- Liz Highleyman | 18 October 2013
The advent of direct-acting antiviral agents can rightly be described as
a revolution in treatment for chronic hepatitis C, but potential challenges
remain – including drug interactions and cost, Heiner Wedemeyer told
participants ...
- Liz Highleyman | 18 October 2013
The dual
CCR5/CCR2 inhibitor cenicriviroc demonstrated good antiviral activity and
tolerability in a phase 2 clinical trial, according to a report at the 14th European AIDS
Conference yesterday in Brussels. The study had ...
- Keith Alcorn | 17 October 2013
The number of people in Europe who have become infected with
a drug-resistant strain of HIV may have increased by around 35% since 2003, even though
the total prevalence of drug resistance ...
- Keith Alcorn | 17 October 2013
Women living with HIV had a higher risk of anal
pre-cancerous changes than cervical changes linked to human papillomavirus (HPV),
French researchers reported at the 14th European AIDS Conference in
Brussels. They suggested ...
- Liz Highleyman | 17 October 2013
Is a functional cure for HIV feasible within the foreseeable future or
is it a hopeless quest robbing resources from more practical approaches to
improve the lives of people living with HIV? ...
- Liz Highleyman | 17 October 2013
The first day of the
14th European AIDS Conference, which opened yesterday in Brussels, featured a
satellite symposium on development of HIV microbicides, broadly defined to
include a variety of approaches to pre-exposure ...